Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Indocyanine Green Fluorescence for Intraoperative Tumor Identification During Resection of Pediatric and Adolescent Intra-Abdominal Malignancy: A Prospective Multi-Institutional Observational Study.

Journal of the American College of Surgeons·2026

Same author

Complications of PI to PIII hemipelvic resections for intermediate and malignant tumours : a systematic review and meta-analysis.

Bone & joint open·2026

Same author

Oncologic outcomes of parenchyma-sparing resection for hepatoblastoma.

Journal of pediatric surgery·2026

Same author

Survivorship After Testicular Cancer in Adolescents and Young Adults: What is Causing Death and When?

The Journal of urology·2026

Same author

Incidence, predictive factors, and proposed classification of wound complications in pediatric extremity bone sarcoma patients following extirpative surgery.

Journal of pediatric surgery·2026

Same author

Outcomes and Surgical Management of Malignant Rhabdoid Tumor of the Kidney: A Report From the Pediatric Surgical Oncology Research Collaborative.

Pediatric blood & cancer·2026

Same journal

Comment on: "The Efficacy and Safety of Bevacizumab/Irinotecan/Temozolomide (BIT) for Relapsed/Refractory Neuroblastoma: The UK Children's Cancer and Leukaemia Group Experience"-The Evolving Role of the BIT Regimen.

Pediatric blood & cancer·2026

Same journal

Extramedullary Intradural Spinal Tumor in an Infant With Neurocutaneous Melanosis.

Pediatric blood & cancer·2026

Same journal

The Role of Hematopoietic Cell Transplantation in Ataxia-Telangiectasia.

Pediatric blood & cancer·2026

Same journal

Pediatric T-Lymphoblastic Lymphoma With T(9;17) and MIR142HG::NOTCH1 Fusion Successfully Treated by Allogeneic Hematopoietic Stem Cell Transplantation in First Complete Remission.

Pediatric blood & cancer·2026

Same journal

Reply to: Comment on: Investigating Biomarkers for Inborn Errors of Immunity in a Prospective Study of Patients With Autoimmune Cytopenia.

Pediatric blood & cancer·2026

Same journal

Comment on: Investigating Biomarkers for Inborn Errors of Immunity in a Prospective Study of Patients With Autoimmune Cytopenia.

Pediatric blood & cancer·2026

See all related articles

Search research articles

Related Experiment Video

Updated: May 5, 2026

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Published on: September 13, 2019

Rhabdomyosarcoma Surgical Update.

Timothy Rogers¹, Andreas Schmidt², Amanda F Buchanan³

¹Department of Paediatric Surgery, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK.

Pediatric Blood & Cancer

|January 14, 2025

Summary

This summary is machine-generated.

Rhabdomyosarcoma (RMS) treatment has improved with advances in surgical resection and chemotherapy. New staging techniques and risk stratification are refining pediatric cancer therapy, though international standardization efforts continue.

Keywords:

local control radiation Level of Evidence: IV rhabdomyosarcoma surgery

More Related Videos

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

Related Experiment Videos

Last Updated: May 5, 2026

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Published on: September 13, 2019

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

Area of Science:

Pediatric Oncology
Surgical Oncology
Cancer Genomics

Background:

Rhabdomyosarcoma (RMS) is a significant pediatric cancer, comprising half of all pediatric sarcomas.
Advances in local control therapy have improved outcomes for RMS patients, including those with metastatic disease.
Current trends include wider use of core needle and sentinel node biopsy for lymph node staging.

Purpose of the Study:

To review recent advancements in Rhabdomyosarcoma (RMS) management.
To highlight the evolution of prognostic factors and risk stratification in RMS.
To discuss ongoing efforts in standardizing care between North American and European surgical oncology groups.

Main Methods:

Review of current therapeutic strategies for Rhabdomyosarcoma.
Analysis of evolving diagnostic and staging techniques, including molecular markers.
Examination of collaborative efforts in surgical oncology cooperative groups.

Main Results:

Improved outcomes in RMS treatment due to enhanced local control and surgical resection strategies.
Increased adoption of advanced biopsy techniques for accurate lymph node staging.
Development of refined prognostic factors, prioritizing fusion status over histology for risk stratification.

Conclusions:

Current therapeutic strategies have significantly improved outcomes for pediatric Rhabdomyosarcoma.
Fusion status is increasingly important for risk stratification, guiding personalized therapy.
Continued international collaboration is essential to overcome philosophical differences and standardize optimal care for RMS patients.